Danaher Corporation $DHR Shares Purchased by UniSuper Management Pty Ltd

Key Points

• UniSuper Management Pty Ltd increased its stake in Danaher Corporation by 1.6%, owning 170,505 shares valued at approximately $34.95 million as of its latest SEC filing.
• Danaher has received multiple analysts' upgrades and downgrades, with an average price target of $246.35 and a "Moderate Buy" rating from equity analysts.
• Despite a net margin of 14.21% and a revenue increase of 3.4% year-over-year, Danaher's stock has fluctuated, with a 12-month low of $171 and a high of $279.90.

UniSuper Management Pty Ltd raised its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 1.6% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 170,505 shares of the conglomerate's stock after buying an additional 2,667 shares during the period. UniSuper Management Pty Ltd's holdings in Danaher were worth $34,954,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of DHR. GHP Investment Advisors Inc. raised its stake in shares of Danaher by 396.0% during the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after buying an additional 99 shares during the last quarter. Heck Capital Advisors LLC purchased a new position in shares of Danaher during the 4th quarter valued at about $27,000. Sierra Ocean LLC raised its stake in shares of Danaher by 116.9% during the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after buying an additional 76 shares during the last quarter. Smallwood Wealth Investment Management LLC purchased a new position in shares of Danaher during the 1st quarter valued at about $31,000. Finally, Dunhill Financial LLC raised its stake in shares of Danaher by 68.4% during the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock valued at $34,000 after buying an additional 67 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Insider Buying and Selling

In related news, Director Teri List sold 2,778 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 11.20% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on DHR. Evercore ISI reduced their price objective on Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Deutsche Bank Aktiengesellschaft cut their price target on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Royal Bank Of Canada set a $241.00 price target on Danaher in a research note on Tuesday, September 2nd. Guggenheim restated a "buy" rating and issued a $250.00 price target on shares of Danaher in a research note on Wednesday, July 23rd. Finally, Wells Fargo & Company cut their price target on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, Danaher presently has an average rating of "Moderate Buy" and an average price target of $246.35.

Danaher Price Performance

Shares of Danaher stock traded down $4.39 on Tuesday, hitting $194.24. 3,344,891 shares of the company were exchanged, compared to its average volume of 2,899,976. The stock has a market capitalization of $139.09 billion, a price-to-earnings ratio of 41.33, a price-to-earnings-growth ratio of 2.77 and a beta of 0.75. The company has a 50-day moving average price of $201.82 and a 200 day moving average price of $199.20. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.90. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm had revenue of $5.94 billion for the quarter, compared to analysts' expectations of $5.83 billion. During the same period in the prior year, the firm posted $1.72 earnings per share. The firm's quarterly revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, sell-side analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.7%. Danaher's dividend payout ratio is presently 27.23%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.